跳到正文
Caixin Global (@caixin)· Caixin Global·· 7 小时前AI 评分51

财新深度:中国首个基因疗法降价50%后仍难寻买方

In Depth: One injection could spare hemophilia patients years of repeated treatment. But even after a 50% price cut, China’s insurers and patients ar...

AI 导读

财新深度报道中国首个基因疗法,一针注射可让血友病患者免于多年反复治疗,但即使降价50%,保险方和患者仍难以负担高昂费用。

来源:Caixin Global (@caixin) · x.com